---
title: "Novelix Pharmaceuticals Ltd (536565) — Share Price, Financials & Analysis"
symbol: "536565"
company: "Novelix Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/536565"
isin: "INE314I01036"
nse_symbol: "TRIMURTHILTD"
bse_code: "536565"
sector: "Retail"
industry: "Pharmacy Retail"
market_cap_cr: 212.15
generated_at: "2026-09-13T19:37:40.896Z"
---

# Novelix Pharmaceuticals Ltd (536565)

Canonical page: https://tapetide.com/stocks/536565

## Company

- **NSE Symbol:** TRIMURTHILTD
- **BSE Code:** 536565
- **ISIN:** INE314I01036
- **Sector:** Retail
- **Industry:** Pharmacy Retail
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** trimurthidrugs.com

## About

Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:49:03.220720Z.

- **Market Cap:** ₹212.15 Cr
- **Classification:** Microcap
- **P/E (reported):** 59.1
- **EPS (TTM):** ₹1.87
- **Book Value:** ₹23.08
- **Price to Book:** 3.25
- **Dividend Yield:** 0%
- **ROE:** -26.4%
- **ROCE:** -26.06%
- **Debt to Equity:** 0.09
- **Revenue (yearly):** ₹9.2 Cr
- **Net Income:** ₹-2 Cr
- **EBITDA:** ₹-2 Cr
- **52-Week High:** ₹92
- **52-Week Low:** ₹38
- **RSI (14):** 45.71

## Tapetide Score

- **Score:** 48 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 39.4 (of 4473 scored stocks)
- **Confidence:** 93%
- **Data coverage:** 86%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 63.11 | 9% |
| growth | 98.9 | 9% |
| momentum | 93.9 | 12% |
| ownership | 64.25 | 24% |
| quality | 9.82 | 22% |
| valuation | 21.62 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company is expected to give good quarter
- Promoter holding has increased by 4.86% over last quarter.
- Company's median sales growth is 42.1% of last 10 years
- Company's working capital requirements have reduced from 222 days to 122 days

### Weaknesses

- Stock is trading at 3.51 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.12% over last 3 years.
- Company has high debtors of 163 days.
- Promoter holding has decreased over last 3 years: -12.6%

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 0% | 152.38% | 329.73% |
| ebitda margin growth | 0% | 317.35% | — | — |
| net income growth | -100% | -47.37% | 255% | 23% |
| revenue growth | -7.14% | -4.17% | 310% | 152% |
| roce | 66.67% | -47.7% | — | -15.41% |
| roe | 66.67% | -48.34% | -26.61% | 777.08% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0.93 | 0.5 | 0.84 | 0.6 | 3.96 | 5.3 | 20.86 | 22.35 | 36.36 | 48.4 | 25.19 | 36.91 |
| Expenses | 1.04 | 0.61 | 0.69 | 1.04 | 3.74 | 5.17 | 20.63 | 22.17 | 35.66 | 47.09 | 23.91 | 35.6 |
| Operating Profit | -0.11 | -0.11 | 0.15 | -0.44 | 0.22 | 0.13 | 0.23 | 0.18 | 0.7 | 1.31 | 1.28 | 1.31 |
| OPM % | -11.83 | -22 | 17.86 | -73.33 | 5.56 | 2.45 | 1.1 | 0.81 | 1.93 | 2.71 | 5.08 | 3.55 |
| Other Income | 0.05 | 0.09 | 0.13 | 0.1 | -0.08 | 0 | 0 | 0 | 0.03 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.12 |
| Depreciation | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 | 0.02 | 0.01 | 0.01 | 0.03 | 0.05 | 0.07 |
| Profit before tax | -0.07 | -0.03 | 0.27 | -0.34 | 0.14 | 0.13 | 0.21 | 0.17 | 0.72 | 1.28 | 1.23 | 1.12 |
| Tax % | 0 | 0 | 0 | 2.94 | 0 | -15.38 | 14.29 | 41.18 | 26.39 | 21.88 | 26.02 | -5.36 |
| Net Profit | -0.07 | -0.03 | 0.28 | -0.35 | 0.13 | 0.15 | 0.18 | 0.11 | 0.53 | 1 | 0.91 | 1.18 |
| EPS in Rs | -0.09 | -0.04 | 0.35 | -0.35 | 0.13 | 0.15 | 0.18 | 0.09 | 0.37 | 0.58 | 0.43 | 0.49 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 3 | 4 | 2 | 1 | 1 | 2 | 4 | 31 | 132 | 147 |
| Expenses | 3 | 3 | 1 | 4 | 3 | 2 | 4 | 31 | 129 | 142 |
| Operating Profit | 0 | 0 | 0 | -3 | -2 | 0 | 0 | 0 | 3 | 5 |
| OPM % | 15 | 6 | 12 | -244 | -151 | 0 | -6 | 0.5 | 2.6 | 3.1 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | -3 | -2 | 0 | 0 | 0 | 3 | 4 |
| Tax % | 34 | -32 | 20 | 0 | -1 | 0 | 50 | 33 | 25 | — |
| Net Profit | 0 | 0 | 0 | -3 | -2 | 0 | 0 | 0 | 3 | 4 |
| EPS in Rs | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.01 | 0.08 | 1.21 | 1.87 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 21 |
| Reserves | 3 | 4 | 4 | 4 | 1 | -1 | -1 | -1 | 8 | 25 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 42 |
| Total Liabilities | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |
| Fixed Assets | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 2 | 3 | 3 | 4 | 4 | 1 | 3 | 3 | 0 | 0 |
| Other Assets | 9 | 9 | 9 | 8 | 5 | 5 | 4 | 4 | 27 | 89 |
| Total Assets | 12 | 12 | 12 | 12 | 9 | 7 | 7 | 7 | 27 | 92 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -1 | 1 | 0 | 1 | 1 | 1 | -2 | 0 | -14 | -22 |
| Cash from Investing Activity | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | -2 |
| Cash from Financing Activity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 26 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 1 | 1 | -2 | 0 | 1 | 2 |
| Free Cash Flow | -1 | 1 | 0 | 1 | 0 | -1 | -2 | 0 | -14 | -26 |
| CFO/OP | -535 | 225 | -220 | 672 | -18 | -34 | — | 136 | -9771 | -643 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 40 | 130 | 216 | 19 | 25 | 32 | 36 | 1 | 216 | 163 |
| Inventory Days | 28 | 19 | 13 | 39 | 89 | 239 | 222 | 113 | 10 | 42 |
| Days Payable | 0 | 54 | 13 | 5 | 4 | 0 | 14 | 0 | 115 | 116 |
| Cash Conversion Cycle | 68 | 95 | 216 | 54 | 111 | 271 | 244 | 114 | 111 | 88 |
| Working Capital Days | 863 | 932 | 858 | 1711 | 819 | 647 | 743 | 346 | 197 | 122 |
| ROCE % | 1 | 3 | 1 | 1 | -31 | -19 | -1 | 0 | 1 | 10 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 66.92% | 66.92% | 66.92% | 66.54% | 66.56% | 66.56% | 66.56% | 52.75% | 54.82% | 51.98% | 49.43% | 50.57% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 21.12% | 21.12% | 22.67% | 21.46% | 20.12% | 20.06% | 20.06% | 36.84% | 39.06% | 42.69% | 46.42% | 45.71% |
| Others | 11.95% | 11.95% | 10.41% | 12% | 13.32% | 13.38% | 13.38% | 10.42% | 6.13% | 5.33% | 4.15% | 3.72% |
| No. of Shareholders | 2389 | 2621 | 2635 | 2579 | 2533 | 2502 | 2484 | 2481 | 2770 | 2994 | 2975 | 3004 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 8 / 6 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 78.27 | Sell |
| EMA (10) | 77.69 | Sell |
| SMA (20) | 78.39 | Sell |
| EMA (20) | 77.41 | Buy |
| SMA (50) | 73.63 | Buy |
| EMA (50) | 74.71 | Buy |
| SMA (100) | 68.93 | Buy |
| EMA (100) | 70.4 | Buy |
| SMA (200) | 63.48 | Buy |
| EMA (200) | 63.31 | Buy |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 51.55 | Neutral |
| MACD (12,26,9) | 0.83 | Sell |
| Stochastic (14,3,3) | 29.89 | Neutral |
| ADX (14) | 25.91 | Buy |
| Williams %R (14) | -52.38 | Neutral |
| ATR (14) | 4.27 | High Volatility |
| ROC (12) | -4.14 | Sell |
| Stoch RSI (14) | 30.13 | Neutral |
| UO (7,14,28) | 50.1 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-09 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=caa03f19-d81a-4e9f-9d0f-7c1ef8925737.pdf) |
| 2026-09-07 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=400eeb35-7f0d-405a-9e63-2b2b3545454c.pdf) |
| 2026-09-07 | [Shareholders Meeting- Notice Of Annual General Meeting To Be Held On Wednesday 30Th September 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebbbf9cf-f16c-460d-b831-ec978960a99c.pdf) |
| 2026-09-07 | [Announcement Under Regulation 30 (LODR)- Letter Of Annual Report & AGM Notice Weblink](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6291f43-3aed-427f-9a5b-66ed2840121d.pdf) |
| 2026-08-31 | [Announcement under Regulation 30 (LODR)-Change in Directorate](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ec40b32-c969-4c5d-80ad-124c0df93f0e.pdf) |
| 2026-08-31 | [Shareholders Meeting AGM On 30Th September 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe7f20d4-23b2-4300-b726-cd3e992cfbc5.pdf) |
| 2026-08-29 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday 29Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fb8e0015-ef4c-4e5d-b8c1-98b04d18ec40.pdf) |
| 2026-08-25 | [Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On Saturday 29Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db7dddfc-1988-4d12-89a1-331c7382c0de.pdf) |
| 2026-08-20 | [Announcement Under Regulation 30 (LODR) - Lease Deed](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e0a88de4-3a34-4f54-af3b-acffb0f8c9dc.pdf) |
| 2026-08-16 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8dd1f591-b3cc-4b5a-94b8-32ec97b38ea9.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Results- Financial Results For June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8466f148-025f-4f68-ac51-a196d3a6f5f2.pdf) |
| 2026-05-29 | [Results- Financial Results For March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7cde346-a268-457e-a986-34afcdb2ac08.pdf) |
| 2026-02-14 | [Results- Revised Financial Results For December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d402b93-a54f-4d2b-9bce-021979d3e51a.pdf) |
| 2026-02-12 | [Results- Financial Results For December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ffb69324-f183-478a-ba85-9c5b8efd08a5.pdf) |
| 2025-11-13 | [Results- Financial Results For September 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c4fd94c6-e8fd-4ef8-83fe-8ee9990539e3.pdf) |
| 2025-08-14 | [Results- Financial Results For June 30 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec3436a1-62e3-457b-943a-68baf4b54dae.pdf) |
| 2025-05-27 | [Results- Financial Results For March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4672f3a-46fc-4839-b6b3-68cb1917c6f7.pdf) |
| 2025-02-13 | [Financial Result For 31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09eed4ed-120b-4d73-b129-8453e10e4614.pdf) |
| 2024-11-13 | [Financial Results For The Quarter And Half Yearly Ended 30Th September, 2024 - Regulation 33(3)(A) Of SEBI (LODR) Regulations, 2015](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7f203b1-8e13-46dc-a24e-762af3a06686.pdf) |
| 2024-08-08 | [Results For The Quarter Ended 30.06.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=161744c7-6f5a-4e1c-b8ee-5b36ec350618.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Shivanshu Mehta will hold interim Chief Business Officer charge at MCX from April 1, 2026. | [Additional Charge Assigned To KMP 9h - Shivanshu Mehta will hold interim Chief Business Officer charge at MCX from April 1, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a2b03534-a3a2-4ae3-aa58-b787737bff4c.pdf) |
| 9 Apr - Submitted Regulation 74(5) depository certificate for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr - Submitted Regulation 74(5) depository certificate for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d885174d-6aa4-4b66-99bc-2152a8f2f0a0.pdf) |
| 8h - 11,50,000 equity shares allotted at Rs20 each on 30 March 2026; non-exec director resigned. | [Board Meeting Outcome for Outcome Of Board Meeting Held On 30Th April, 2026 8h - 11,50,000 equity shares allotted at Rs20 each on 30 March 2026; non-exec director resigned.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/09dbbb09-a1bb-4081-b0a1-e09eadb786ff.pdf) |
| 5 May - Company intimates official website https://novelixpharma.com under Regulation 30/46 compliance. | [Intimation Under Regulation 30 (LODR) Regulations, 2015- Website Address. 5 May - Company intimates official website https://novelixpharma.com under Regulation 30/46 compliance.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/41b7e897-3242-42e7-bda2-1d6c385ab25f.pdf) |
| 31 Mar - Reconstituted Audit, Nomination & Remuneration, Stakeholders committees; Janardhan D. Kabra chair; effective 30 March 2026. | [Intimation Under Regulation 30 (LODR), Regulations 2015- Reconstitution Of Committees. 31 Mar - Reconstituted Audit, Nomination & Remuneration, Stakeholders committees; Janardhan D. Kabra chair; effective 30 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f84863c8-4345-4213-ba09-e6533aa96489.pdf) |
| 31 Mar - Non-executive director Jivamohan Divakar Valluri resigned effective 30 March 2026; left Audit, NRC, Stakeholders committees. | [Announcement under Regulation 30 (LODR)-Resignation of Director 31 Mar - Non-executive director Jivamohan Divakar Valluri resigned effective 30 March 2026; left Audit, NRC, Stakeholders committees.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/eba16316-dfc1-4a87-9bf7-86bc43b36993.pdf) |
| 31 Mar - Allotment of 1,150,000 equity shares @ Rs20 on 30 Mar 2026; Rs1,72,50,000 received. | [Announcement under Regulation 30 (LODR)-Allotment 31 Mar - Allotment of 1,150,000 equity shares @ Rs20 on 30 Mar 2026; Rs1,72,50,000 received.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/74bd9491-efe0-40cb-8ab2-1d7663e7a5f8.pdf) |
| 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5ff3d51c-7e12-408a-84dc-226bdd2c36f9.pdf) |
| 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5ff3d51c-7e12-408a-84dc-226bdd2c36f9.pdf) |
| 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 28 Apr - Novelix Pharmaceuticals confirms it is not a large corporate as of 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/5ff3d51c-7e12-408a-84dc-226bdd2c36f9.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2022 | [Concall - Sep 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a06224a5-9f35-4a4e-b0f4-e38bf3ede305.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b4e63718-4805-4af7-aa20-56e9523d67a1.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/288b4e65-3d02-4539-b24a-4ca545814222.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7c10dac6-029c-45d7-8018-a10e28a22f3d.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2c158b96-fcb0-4de6-8363-76034d62f969.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/754f054d-d089-4dc8-a595-0767e897e71e.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ddd5b4eb-71ad-436c-8f8c-926e07ca02e1.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/695a0d80-f511-4d72-b334-bc2ab6d528ff.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7ed16f93-ce57-4e3c-8935-33783a06aa48.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/688d77a1-6c93-4ff9-b6c3-29f12e890b27.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1964d311-8c37-49f4-9adb-15656f97d00b.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b927febe-b0ef-465f-ab32-cb533fd7e943.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dab2bb62-4eb1-40c6-b41a-f4c1b8afcc43.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8a0875bb-5a12-4d21-8f17-4a873ebb4823.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fc21bc30-1ab7-4b24-b713-a8574fb7cb94.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f5b856b7-d384-4824-b5ce-ffe1c855ff54.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:37:40.896Z.